This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Self-injuring young girls overestimate ... Adolescent girls who self-injure feel that they receive more ... (21 Jul 2019)
Depressed by Facebook and the like The answers to the question of whether using social networks can ... (19 Jul 2019)
Testosterone replacement therapy (TRT) can ... Caution is warranted before prescribing TRT for men older than ... (19 Jul 2019)
Changes in food industry salt regulations ... A relaxation of UK industry regulation of salt content in food ... (17 Jul 2019)
Osteoarthritis linked to higher risk of ... Researchers at Lund University in Sweden have investigated the ... (17 Jul 2019)
Rate this item
(0 votes)
The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Mazza A 1, Schiavon L , Rigatelli G , Torin G , Montanaro F , Lenti S . Background - The clinical hypocholesterolemic effect of nutraceutical compounds (NCs) containing red yeast rice extracts providing a daily dose of 2.5-10 mg of monacolin K is now well established. For this reason, NCs may be a viable alternative to the statin drugs commonly used to lower cholesterol levels. However, in order to avoid some possible statin-like side effects, most NCs available on the market contain low doses of monacolin K, which could reduce their efficacy. The aim of this study was to investigate the efficacy and safety of a NC containing high doses of monacolin K (10 mg) in improving the lipid profile and glucose metabolism when added to the diet versus the diet alone in a group of hypertensive and hyper-cholesterolemic subjects at low cardiovascular risk. Methods - Thirty subjects with grade-1 essential hypertension (mean age 51.5 ± 7.8 years, 62.9% males) were enrolled in the treatment group (NC group). These subjects followed a programmed diet and took one tablet…
Rate this item
(2 votes)
Meningococcal Group B (MenB) is Responsible for 60 Percent of Meningococcal Disease Cases in Adolescents and Young Adults in Europe[1]  
Rate this item
(0 votes)
On the 15th June, a new glaucoma procedure was performed for the first time in Malta, as part of a surgeon training session organised by Allergan. The new XEN implant forms part of Allergan’s Eyecare portfolio distributed by Vivian Corporation.
Page 1 of 3

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…